Global Butorphanol Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Butorphanol Market Research Report 2024
Butorphanol is a morphinan-type synthetic agonist–antagonist opioid analgesic developed by Bristol-Myers. Butorphanol is available as the tartrate salt in injectable, tablet, and intranasal spray formulations. The tablet form is only used in dogs, cats and horses due to low bioavailability in humans.
According to Mr Accuracy reports’s new survey, global Butorphanol market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Butorphanol market research.
Key manufacturers engaged in the Butorphanol industry include Hikma Pharmaceuticals, Athanas Enterprise Private Limited, Pfizer, Apothecon Pharmaceuticals, Mylan, Novex Pharma, Bristol Myers Squibb, Sanochemia Pharmazeutika and Selectavet, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Butorphanol were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Butorphanol market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Butorphanol market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Hikma Pharmaceuticals
Athanas Enterprise Private Limited
Pfizer
Apothecon Pharmaceuticals
Mylan
Novex Pharma
Bristol Myers Squibb
Sanochemia Pharmazeutika
Selectavet
Richter Pharma Ag
Troy Laboratories Nz
Animedica
Boehringer Ingelheim Santé Animale
Ausrichter
Zoetis
Dechra Pharmaceuticals
Faunapharma
Merck KGaA
Segment by Type
Spray
Injection
Tablet
Human
Veterinary
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Butorphanol report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Butorphanol market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Butorphanol market research.
Key manufacturers engaged in the Butorphanol industry include Hikma Pharmaceuticals, Athanas Enterprise Private Limited, Pfizer, Apothecon Pharmaceuticals, Mylan, Novex Pharma, Bristol Myers Squibb, Sanochemia Pharmazeutika and Selectavet, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Butorphanol were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Butorphanol market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Butorphanol market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Hikma Pharmaceuticals
Athanas Enterprise Private Limited
Pfizer
Apothecon Pharmaceuticals
Mylan
Novex Pharma
Bristol Myers Squibb
Sanochemia Pharmazeutika
Selectavet
Richter Pharma Ag
Troy Laboratories Nz
Animedica
Boehringer Ingelheim Santé Animale
Ausrichter
Zoetis
Dechra Pharmaceuticals
Faunapharma
Merck KGaA
Segment by Type
Spray
Injection
Tablet
Segment by Application
Human
Veterinary
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Butorphanol report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source